Piramal moves to commercialize amyloid tracer in Korea

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

The PET amyloid imaging agent florbetaben F-18 may soon be available in South Korea as a result of a licensing agreement and partnership between producer Piramal Imaging and Ci-Co Healthcare, according to a Nov. 21 announcement from Piramal.

Ci-Co, as strategic partner and agent, will be charged with obtaining authorization to commercialize and market the radiotracer from the Korean Health Authorities. Manufacturing and supply are planned with South Korean radiopharmacy network DuChemBio.

"Piramal Imaging is committed to building a global presence in nuclear medicine and making florbetaben F-18 available to patients around the world. Ci-Co Healthcare shares Piramal Imaging's dedication and we look forward to a strong partnership that will allow both companies to achieve its goals," said Piramal board member Ludger Dinkelborg, in a release.

Kathy Mahdoubi

Related Content

PET method offers new insight into inflammation of the brain
New PET imaging method could improve our understanding of long COVID
FDA approves new prostate cancer imaging agent with extended shelf life
New PET study offers insight into how dopamine drives executive function
New radiopharmaceutical targeted at gastrointenstinal cancers yields impressive results
New PET method combines antibody with radioactive isotope to improve lung cancer detection

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.